| Products | Business Development | News | Contact |
|
||
News
F-Star Buys Back Royalty Obligations. TVM Capital Joins Investor Syndicate
f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, announced today that it has acquired future royalty obligations to New Century Pharmaceuticals (NCP) via a one-off payment. In the course of the transaction, TVM Capital, a transatlantic venture capital firm based in Munich and Boston, acquired NCP’s minority stake in f-star.
F-Star Opens Second Research Site in Cambridge, UK
f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, announced today that it has acquired future royalty obligations to New Century Pharmaceuticals (NCP) via a one-off payment. In the course of the transaction, TVM Capital, a transatlantic venture capital firm based in Munich and Boston, acquired NCP’s minority stake in f-star.
F-Star Appoints Three Pioneers in Antibody Engineering and Development to its Newly Established Scientific Advisory Board
f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, announced today that it has established a Scientific Advisory Board and has appointed three outstanding scientists and pioneers in the field of antibody engineering and development to form the nucleus of this advisory body. Members of f-star's Scientific Advisory Board include Professor Sir Ravinder Maini, Professor Anthony Rees and Professor Sir Gregory Winter.
Press Release December 12, 2007
F-Star Raises EUR 3.0 million in a Second Closing of its Series A Financing Round from Novo A/S
f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, today announced that it has raised EUR 3.0 million from Novo A/S in a Second Closing of its Series A financing round, originally co-led by Aescap Venture and Atlas Venture. After this Second Closing, the amount raised in the Series A round increases to EUR 9.0 million. In total, the Company has raised EUR 13.0 million since inception in 2006.
Press Release November 28, 2007
F-Star Appoints Geert Mudde as Chief Scientific Officer
f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, today announced the appointment of Dr. Geert Mudde as Chief Scientific Officer. Dr. Mudde has over 20 years of experience in the biotech and pharmaceutical industry, specializing in preclinical research and development. He comes to f-star from Baxter BioScience, where he was Director of Discovery Research and Technical Assessment.
Press Release September 25, 2007
F-Star Raises EUR 6.0 million in Series A Financing from Aescap Venture and Atlas Venture
f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, today announced that it has raised EUR 6.0 million in a Series A financing from Aescap Venture and Atlas Venture. The financing comes just 8 months after f-star raised a EUR 1.5m Seed financing from Atlas Venture, and little more than one year after the company's inception. Including loans and grants from Austrian government agencies, the company has raised EUR 10.0m so far.
Press Release September 10, 2007
EUR 1.5m seed financing from Atlas Venture
f-star, a biopharmaceutical company founded in 2006 to develop and exploit an innovative antibody engineering technology, today announced that it raised EUR1.5 million in seed financing from Atlas Venture, a leading early-stage international venture capital firm. Prior to the most recent investment of EUR1.5 million by Atlas Venture, f-star has secured pre-seed and seed financing in excess of EUR1.1 million, including loans and grants from AWS, FFG and inits, Austrian agencies for the promotion of research, technology and innovation.
Press Release January 8, 2007
f-star starts its operations
f-star starts its operations with an industry experienced management team. The company is optimizing its "modular antibody" technology and preparing for its own therapeutics product pipeline. f-star has signed a contract with the University of Applied Life Sciences that allows the company to use laboratory space and infrastructure at the University until f-star has established its own, independent facilities. The office is located close to the labs in the business center "nineteen" at Mooslackengasse 17; A-1190 Vienna, Austria.
Vienna, Austria, June 12, 2006